Quick Search:       Advanced Search
Chinese Version 
Online office
Journal Online
Download
Top
Links

扫描微信二维码,获取更多信息
Clinical and experimental study on treatment of acute respiratory tract infection with Shuanghuanglian Aerosol
  
View Full Text  View/Add Comment  Download reader
KeyWord:
Author NameAffiliation
Yue-Hong Wang Second Affiliated Hospital of Harbin Medical University, 150086, Harbin 
Kai-Jian Xu Second Affiliated Hospital of Harbin Medical University, 150086, Harbin 
Wei-Shi Jiang Second Affiliated Hospital of Harbin Medical University, 150086, Harbin 
Fu-Zhen Lu Second Affiliated Hospital of Harbin Medical University, 150086, Harbin 
Meng-Ying Hu Second Affiliated Hospital of Harbin Medical University, 150086, Harbin 
Zeng-Ke Zhe Second Affiliated Hospital of Harbin Medical University, 150086, Harbin 
Feng Gao Second Affiliated Hospital of Harbin Medical University, 150086, Harbin 
Jing-Wei Zhang Second Affiliated Hospital of Harbin Medical University, 150086, Harbin 
Xiao-Lian He Harbin Municipal Children’s Hospital, Harbin 
Feng-Yang Hong First Affiliated Hospital of Harbin Medical University, Harbin 
Hits: 1211
Download times: 908
Abstract:
      Two hundred and two cases of acute respiratory tract infection (ARI) were treated with Shuanghuanglian (SHL) aerosol. In these cases, the majority were virus infection and 64% of them was caused by the respiratory syncytial virus (RSV). The virostatic and bacteriostatic test were done in vitro by the cell culture method and it was shown that SHL could inhibit the RSV, para-influenza virus I ~ IV and 23 kinds of pathogenic bacteria such as Staphylococcus aureus etc. The bacteriostatic effect was positively correlated to the SHL concentration. Experimental study showed that SHL could enhance the NK cell activity, promote the production of α-interferon and raise the rate of lymphocyte transformation. The controlled observation on SHL preparation with various dosage-forms revealed that the SHL aerosol in treating early ARI showed better results than that of injections and oral liquid symptomatologically (P<0.05). The total effective rate was 96%.
Close